Negotiating renal dysfunction when treating patients with heart failure

References

• Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891–975.
   PubMed Web of Science ®Google Scholar
• Van Riet EE, Hoes AW, Wagenaar KP, et al. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur J Heart Fail.. 2016;18(3):242–252.
   PubMed Web of Science ®Google Scholar
• Crespo-Leiro MG, Anker SD, Maggioni AP, et al. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. Eur J Heart Fail. 2016;18(6):613–625.
   PubMed Web of Science ®Google Scholar
• Thorvaldsen T, Benson L, Dahlstrom U, et al. Use of evidence-based therapy and survival in heart failure in Sweden 2003-2012. Eur J Heart Fail. 2016;18(5):503–511.
   PubMed Web of Science ®Google Scholar
• Lund LH, Donal E, Oger E, et al. Association between cardiovascular vs. non-cardiovascular co-morbidities and outcomes in heart failure with preserved ejection fraction. Eur J Heart Fail. 2014;16(9):992–1001.
   PubMed Web of Science ®Google Scholar
• Triposkiadis F, Giamouzis G, Parissis J, et al. Reframing the association and significance of co-morbidities in heart failure. Eur J Heart Fail. 2016;18(7):744–758.
   PubMed Web of Science ®Google Scholar
• Mebazaa A, Yilmaz MB, Levy P, et al. Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. Eur J Heart Fail. 2015;17(6):544–558.
   PubMed Web of Science ®Google Scholar
• Metra M, Mentz RJ, Chiswell K, et al. Acute heart failure in elderly patients: worse outcomes and differential utility of standard prognostic variables. Insights from the PROTECT trial. Eur J Heart Fail. 2015;17(1):109–118.
   PubMed Web of Science ®Google Scholar
• Christ M, Stork S, Dorr M, et al. Heart failure epidemiology 2000-2013: insights from the German Federal Health Monitoring System. Eur J Heart Fail. 2016;18(8):1009–1018.
   PubMed Web of Science ®Google Scholar
• Mentz RJ, Kelly JP, von Lueder TG, et al. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol. 2014;64(21):2281–2293.
   PubMed Web of Science ®Google Scholar
• van Deursen VM, Urso R, Laroche C, et al. Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. Eur J Heart Fail. 2014;16(1):103–111.
   PubMed Web of Science ®Google Scholar
• Ronco C, Haapio M, House AA, et al. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52(19):1527–1539.
   PubMed Web of Science ®Google Scholar
• Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–1305.
   PubMed Web of Science ®Google Scholar
• Hillege HL, Nitsch D, Pfeffer MA, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006;113(5):671–678.
   PubMed Web of Science ®Google Scholar
• Carubelli V, Metra M, Lombardi C, et al. Renal dysfunction in acute heart failure: epidemiology, mechanisms and assessment. Heart Fail Rev. 2012;17(2):271–282.
   PubMed Web of Science ®Google Scholar
• Lofman I, Szummer K, Hagerman I, et al. Prevalence and prognostic impact of kidney disease on heart failure patients. Open Heart. 2016;3(1):e000324.
   PubMedGoogle Scholar
• Lazzarini V, Bettari L, Bugatti S, et al. Can we prevent or treat renal dysfunction in acute heart failure? Heart Fail Rev. 2012;17(2):291–303.
   PubMed Web of Science ®Google Scholar
• Butler J, Gheorghiade M, Kelkar A, et al. In-hospital worsening heart failure. Eur J Heart Fail. 2015;17(11):1104–1113.
   PubMed Web of Science ®Google Scholar
• Damman K, Valente MA, Voors AA, et al. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. 2014;35(7):455–469.
   PubMed Web of Science ®Google Scholar
• Rebholz CM, Anderson CA, Grams ME, et al. Relationship of the American Heart Association’s Impact Goals (life’s simple 7) with risk of chronic kidney disease: results from the Atherosclerosis Risk in Communities (ARIC) Cohort Study. J Am Heart Assoc. 2016;5(4):e003192.
   PubMed Web of Science ®Google Scholar
• Lam CS, Lund LH. Microvascular endothelial dysfunction in heart failure with preserved ejection fraction. Heart. 2016;102(4):257–259.
   PubMed Web of Science ®Google Scholar
• Group. KDIGOKCGDW. KDIGO 2012 Clinical Practice Guideline for evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–150.
   Web of Science ®Google Scholar
• Schefold JC, Filippatos G, Hasenfuss G, et al. Heart failure and kidney dysfunction: epidemiology, mechanisms and management. Nat Rev Nephrol. 2016;12(10):610–623.
   PubMed Web of Science ®Google Scholar
• McClellan WM, Langston RD, Presley R. Medicare patients with cardiovascular disease have a high prevalence of chronic kidney disease and a high rate of progression to end-stage renal disease. J Am Soc Nephrol. 2004;15(7):1912–1919.
   PubMed Web of Science ®Google Scholar
• Fang JC. Heart failure with preserved ejection fraction: a kidney disorder? Circulation. 2016;134(6):435–437.
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Carson PE, Komajda M, et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur J Heart Fail. 2008;10(2):149–156.
   PubMed Web of Science ®Google Scholar
• Shah SJ, Heitner JF, Sweitzer NK, et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail. 2013;6(2):184–192.
   PubMed Web of Science ®Google Scholar
• Gori M, Senni M, Gupta DK, et al. Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. Eur Heart J. 2014;35(48):3442–3451.
   PubMed Web of Science ®Google Scholar
• Ather S, Chan W, Bozkurt B, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol. 2012;59(11):998–1005.
   PubMed Web of Science ®Google Scholar
• Unger ED, Dubin RF, Deo R, et al. Association of chronic kidney disease with abnormal cardiac mechanics and adverse outcomes in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2016;18(1):103–112.
   PubMed Web of Science ®Google Scholar
• Lofman I, Szummer K, Dahlstrom U, et al. Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction. Eur J Heart Fail.  2017;19(12):1606–1614.
   Web of Science ®Google Scholar
• Ljungman S, Laragh JH, Cody RJ. Role of the kidney in congestive heart failure. Relationship of cardiac index to kidney function. Drugs. 1990;39(Suppl 4):10-21; discussion 2-4.
   PubMedGoogle Scholar
• Singh DK, Winocour P, Farrington K. Mechanisms of disease: the hypoxic tubular hypothesis of diabetic nephropathy. Nat Clin Pract Nephrol. 2008;4(4):216–226.
   PubMedGoogle Scholar
• Hanberg JS, Sury K, Wilson FP, et al. Reduced cardiac index is not the dominant driver of renal dysfunction in heart failure. J Am Coll Cardiol. 2016;67(19):2199–2208.
   PubMed Web of Science ®Google Scholar
• Mullens W, Abrahams Z, Francis GS, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53(7):589–596.
   PubMed Web of Science ®Google Scholar
• Damman K, van Deursen VM, Navis G, et al. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol. 2009;53(7):582–588.
   PubMed Web of Science ®Google Scholar
• Mullens W, Abrahams Z, Skouri HN, et al. Elevated intra-abdominal pressure in acute decompensated heart failure: a potential contributor to worsening renal function? J Am Coll Cardiol. 2008;51(3):300–306.
   PubMed Web of Science ®Google Scholar
• Frea S, Pidello S, Bovolo V, et al. Prognostic incremental role of right ventricular function in acute decompensation of advanced chronic heart failure. Eur J Heart Fail. 2016;18(5):564–572.
   PubMed Web of Science ®Google Scholar
• Maeder MT, Holst DP, Kaye DM. Tricuspid regurgitation contributes to renal dysfunction in patients with heart failure. J Card Fail. 2008;14(10):824–830.
   PubMed Web of Science ®Google Scholar
• Pellicori P, Carubelli V, Zhang J, et al. IVC diameter in patients with chronic heart failure: relationships and prognostic significance. JACC Cardiovasc Imaging. 2013;6(1):16–28.
   PubMed Web of Science ®Google Scholar
• Sinkeler SJ, Damman K, van Veldhuisen DJ, et al. A re-appraisal of volume status and renal function impairment in chronic heart failure: combined effects of pre-renal failure and venous congestion on renal function. Heart Fail Rev. 2012;17(2):263–270.
   PubMed Web of Science ®Google Scholar
• Iida N, Seo Y, Sai S, et al. Clinical implications of intrarenal hemodynamic evaluation by doppler ultrasonography in heart failure. JACC Heart Fail. 2016;4(8):674–682.
   PubMed Web of Science ®Google Scholar
• Kent DM, Jafar TH, Hayward RA, et al. Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol. 2007;18(6):1959–1965.
   PubMed Web of Science ®Google Scholar
• Masuo K, Lambert GW, Esler MD, et al. The role of sympathetic nervous activity in renal injury and end-stage renal disease. Hypertens Res. 2010;33(6):521–528.
   PubMed Web of Science ®Google Scholar
• Edner M, Benson L, Dahlstrom U, et al. Association between renin-angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: a prospective propensity score-matched cohort study. Eur Heart J. 2015;36(34):2318–2326.
   PubMed Web of Science ®Google Scholar
• Kazory A. Emergence of blood urea nitrogen as a biomarker of neurohormonal activation in heart failure. Am J Cardiol. 2010;106(5):694–700.
   PubMed Web of Science ®Google Scholar
• Nymo SH, Hulthe J, Ueland T, et al. Inflammatory cytokines in chronic heart failure: interleukin-8 is associated with adverse outcome. Results from CORONA. Eur J Heart Fail. 2014;16(1):68–75.
   PubMed Web of Science ®Google Scholar
• Carubelli V, Bonadei I, Castrini AI, et al. Prognostic value of the absolute lymphocyte count in patients admitted for acute heart failure. J Cardiovasc Med (Hagerstown). 2017;18(11):859–865.
   Web of Science ®Google Scholar
• Xydonas S, Parissis J, Lioni L, et al. Immunosenescence in patients with chronic systolic heart failure. J Cardiovasc Med (Hagerstown). 2016;17(8):624–630.
   PubMed Web of Science ®Google Scholar
• Lainscak M, Vitale C. Biological and chronological age in heart failure: role of immunosenescence. J Cardiovasc Med (Hagerstown). 2016;17(12):857–859.
   PubMed Web of Science ®Google Scholar
• Sharma R, Coats AJ, Anker SD. The role of inflammatory mediators in chronic heart failure: cytokines, nitric oxide, and endothelin-1. Int J Cardiol. 2000;72(2):175–186.
   PubMed Web of Science ®Google Scholar
• Colombo PC, Ganda A, Lin J, et al. Inflammatory activation: cardiac, renal, and cardio-renal interactions in patients with the cardiorenal syndrome. Heart Fail Rev. 2012;17(2):177–190.
   PubMed Web of Science ®Google Scholar
• Lainscak M, Filippatos GS, Gheorghiade M, et al. Cachexia: common, deadly, with an urgent need for precise definition and new therapies. Am J Cardiol. 2008;101(11A):8E–10E.
   PubMed Web of Science ®Google Scholar
• Stenvinkel P, Larsson TE. Chronic kidney disease: a clinical model of premature aging. Am J Kidney Dis. 2013;62(2):339–351.
   PubMed Web of Science ®Google Scholar
• Moody WE, Edwards NC, Chue CD, et al. Arterial disease in chronic kidney disease. Heart. 2013;99(6):365–372.
   PubMed Web of Science ®Google Scholar
• Ter Maaten JM, Damman K, Verhaar MC, et al. Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation. Eur J Heart Fail. 2016;18(6):588–598.
   PubMed Web of Science ®Google Scholar
• Munzel T, Gori T, Keaney JF Jr., et al. Pathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implications. Eur Heart J. 2015;36(38):2555–2564.
   PubMed Web of Science ®Google Scholar
• Ter Maaten JM, Voors AA. Renal dysfunction in heart failure with a preserved ejection fraction: cause or consequence? Eur J Heart Fail. 2016;18(1):113–114.
   PubMed Web of Science ®Google Scholar
• Nayor M, Larson MG, Wang N, et al. The association of chronic kidney disease and microalbuminuria with heart failure with preserved vs. reduced ejection fraction. Eur J Heart Fail. 2017;19(5):615–623.
   PubMed Web of Science ®Google Scholar
• Sanders-van Wijk S, Van Empel V, Davarzani N, et al. Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction. Eur J Heart Fail. 2015;17(10):1006–1014.
   PubMed Web of Science ®Google Scholar
• Groenveld HF, Januzzi JL, Damman K, et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol. 2008;52(10):818–827.
   PubMed Web of Science ®Google Scholar
• Silverberg DS. The role of erythropoiesis stimulating agents and intravenous (IV) iron in the cardio renal anemia syndrome. Heart Fail Rev. 2011;16(6):609–614.
   PubMed Web of Science ®Google Scholar
• von Haehling S, Anker SD. Cardio-renal anemia syndrome. Contrib Nephrol. 2011;171:266–273.
   PubMed Web of Science ®Google Scholar
• Ebner N, Jankowska EA, Ponikowski P, et al. The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic heart failure. Results from the studies investigating co-morbidities aggravating heart failure. Int J Cardiol. 2016;205:6–12.
   PubMed Web of Science ®Google Scholar
• Klip IT, Comin-Colet J, Voors AA, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. 2013;165(4):575–82.e3.
   PubMed Web of Science ®Google Scholar
• Jankowska EA, Tkaczyszyn M, Suchocki T, et al. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. Eur J Heart Fail. 2016;18(7):786–795.
   PubMed Web of Science ®Google Scholar
• Swedberg K, Young JB, Anand IS, et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med. 2013;368(13):1210–1219.
   PubMed Web of Science ®Google Scholar
• Damman K, Navis G, Voors AA, et al. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail. 2007;13(8):599–608.
   PubMed Web of Science ®Google Scholar
• Metra M, Nodari S, Parrinello G, et al. Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. Eur J Heart Fail. 2008;10(2):188–195.
   PubMed Web of Science ®Google Scholar
• Adams KF, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149(2):209–216.
   PubMed Web of Science ®Google Scholar
• Fonarow GC, Stough WG, Abraham WT, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol. 2007;50(8):768–777.
   PubMed Web of Science ®Google Scholar
• Metra M, Davison B, Bettari L, et al. Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. Circ Heart Fail. 2012;5(1):54–62.
   PubMed Web of Science ®Google Scholar
• Testani JM, Chen J, McCauley BD, et al. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation. 2010;122(3):265–272.
   PubMed Web of Science ®Google Scholar
• Breidthardt T, Weidmann ZM, Twerenbold R, et al. Impact of haemoconcentration during acute heart failure therapy on mortality and its relationship with worsening renal function. Eur J Heart Fail. 2017;19(2):226–236.
   PubMed Web of Science ®Google Scholar
• Palazzuoli A, Lombardi C, Ruocco G, et al. Chronic kidney disease and worsening renal function in acute heart failure: different phenotypes with similar prognostic impact?. Eur Heart J Acute Cardiovasc Care. 2016;5(8):534–548.
   Web of Science ®Google Scholar
• Carubelli V, Lombardi C, Gorga E, et al. Cardiorenal Interactions. Heart Fail Clin. 2016;12(3):335–347.
   PubMed Web of Science ®Google Scholar
• Sokolski M, Zymlinski R, Biegus J, et al. Urinary levels of novel kidney biomarkers and risk of true worsening renal function and mortality in patients with acute heart failure. Eur J Heart Fail. 2017;19(6):760–767.
   Web of Science ®Google Scholar
• Demissei BG, Cotter G, Prescott MF, et al. A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial. Eur J Heart Fail. 2017;19(8):1001–1010.
   Web of Science ®Google Scholar
• Boudoulas KD, Triposkiadis F, Parissis J, et al. The cardio-renal interrelationship. Prog Cardiovasc Dis.  2017;59(6):636–648.
   Web of Science ®Google Scholar
• O’Connor CM, Mentz RJ, Cotter G, et al. The PROTECT in-hospital risk model: 7-day outcome in patients hospitalized with acute heart failure and renal dysfunction. Eur J Heart Fail. 2012;14(6):605–612.
   PubMed Web of Science ®Google Scholar
• Lombardi C, Carubelli V, Rovetta R, et al. Prognostic value of serial measurements of blood urea nitrogen in ambulatory patients with chronic heart failure. Panminerva Med. 2016;58(1):8–15.
   Web of Science ®Google Scholar
• Boudoulas KD, Triposkiadis F, Parissis J, et al. The cardio-renal interrelationship. Prog Cardiovasc Dis. 2017;59(6):636–648.
   PubMed Web of Science ®Google Scholar
• Damman K, Solomon SD, Pfeffer MA, et al. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme. Eur J Heart Fail. 2016;18(12):1508–1517.
   PubMed Web of Science ®Google Scholar
• Ljungman S, Kjekshus J, Swedberg K. Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). Am J Cardiol. 1992;70(4):479–487.
   PubMed Web of Science ®Google Scholar
• Blair JE, Pang PS, Schrier RW, et al. Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur Heart J. 2011;32(20):2563–2572.
   PubMed Web of Science ®Google Scholar
• Giatras I, Lau J, Levey AS. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Ann Intern Med. 1997;127(5):337–345.
   PubMed Web of Science ®Google Scholar
• Ayalasomayajula SP, Langenickel TH, Jordaan P, et al. Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor. Eur J Clin Pharmacol. 2016;72(9):1065–1073.
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004.
   PubMed Web of Science ®Google Scholar
• Voors AA, Gori M, Liu LC, et al. Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2015;17(5):510–517.
   PubMed Web of Science ®Google Scholar
• Axelsson J, Rippe A, Rippe B. Transient and sustained increases in glomerular permeability following ANP infusion in rats. Am J Physiol Renal Physiol. 2011;300(1):F24–30.
   PubMed Web of Science ®Google Scholar
• Canaan-Kuhl S, Ostendorf T, Zander K, et al. C-type natriuretic peptide inhibits mesangial cell proliferation and matrix accumulation in vivo. Kidney Int. 1998;53(5):1143–1151.
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–717.
   PubMed Web of Science ®Google Scholar
• Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11–21.
   PubMed Web of Science ®Google Scholar
• Rossignol P, Dobre D, McMurray JJ, et al. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail. 2014;7(1):51–58.
   PubMed Web of Science ®Google Scholar
• Eschalier R, McMurray JJ, Swedberg K, et al. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol. 2013;62(17):1585–1593.
   PubMed Web of Science ®Google Scholar
• Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351(6):543–551.
   PubMed Web of Science ®Google Scholar
• Pitt B, Bakris GL, Bushinsky DA, et al. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail. 2015;17(10):1057–1065.
   PubMed Web of Science ®Google Scholar
• Anker SD, Kosiborod M, Zannad F, et al. Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. Eur J Heart Fail. 2015;17(10):1050–1056.
   PubMed Web of Science ®Google Scholar
• Ghali JK, Wikstrand J, Van Veldhuisen DJ, et al. The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT-HF). J Card Fail. 2009;15(4):310–318.
   PubMed Web of Science ®Google Scholar
• Cao G, Llambi HG, Ottaviano G, et al. Carvedilol protects the peritubular capillaries and kidney structure in spontaneously hypertensive rats. Int J Cardiol. 2015;181:415–416.
   PubMed Web of Science ®Google Scholar
• Felker GM, Mentz RJ. Diuretics and ultrafiltration in acute decompensated heart failure. J Am Coll Cardiol. 2012;59(24):2145–2153.
   PubMed Web of Science ®Google Scholar
• Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364(9):797–805.
   PubMed Web of Science ®Google Scholar
• Ambrosy AP, Pang PS, Khan S, et al. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. Eur Heart J. 2013;34(11):835–843.
   PubMed Web of Science ®Google Scholar
• Kociol RD, McNulty SE, Hernandez AF, et al. Markers of decongestion, dyspnea relief, and clinical outcomes among patients hospitalized with acute heart failure. Circ Heart Fail. 2013;6(2):240–245.
   PubMed Web of Science ®Google Scholar
• Coiro S, Rossignol P, Ambrosio G, et al. Prognostic value of residual pulmonary congestion at discharge assessed by lung ultrasound imaging in heart failure. Eur J Heart Fail. 2015;17(11):1172–1181.
   PubMed Web of Science ®Google Scholar
• Carubelli V, Lombardi C, Lazzarini V, et al. N-terminal pro-B-type natriuretic peptide-guided therapy in patients hospitalized for acute heart failure. J Cardiovasc Med (Hagerstown). 2016;17(11):828–839.
   PubMed Web of Science ®Google Scholar
• Salah K, Kok WE, Eurlings LW, et al. Competing risk of cardiac status and renal function during hospitalization for acute decompensated heart failure. JACC Heart Fail. 2015;3(10):751–761.
   PubMed Web of Science ®Google Scholar
• ter Maaten JM, Valente MA, Damman K, et al. Diuretic response in acute heart failure-pathophysiology, evaluation, and therapy. Nat Rev Cardiol. 2015;12(3):184–192.
   PubMed Web of Science ®Google Scholar
• Testani JM, Brisco MA, Turner JM, et al. Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure. Circ Heart Fail. 2014;7(2):261–270.
   PubMed Web of Science ®Google Scholar
• Valente MA, Voors AA, Damman K, et al. Diuretic response in acute heart failure: clinical characteristics and prognostic significance. Eur Heart J. 2014;35(19):1284–1293.
   PubMed Web of Science ®Google Scholar
• ter Maaten JM, Dunning AM, Valente MA, et al. Diuretic response in acute heart failure-an analysis from ASCEND-HF. Am Heart J. 2015;170(2):313–321.
   PubMed Web of Science ®Google Scholar
• Voors AA, Davison BA, Teerlink JR, et al. Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome – an analysis from RELAX-AHF. Eur J Heart Fail. 2014;16(11):1230–1240.
   PubMed Web of Science ®Google Scholar
• Testani JM, Brisco MA, Kociol RD, et al. Substantial discrepancy between fluid and weight loss during acute decompensated heart failure treatment. Am J Med. 2015;128(7):776–83 e4.
   PubMed Web of Science ®Google Scholar
• Lopez B, Gonzalez A, Beaumont J, et al. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol. 2007;50(9):859–867.
   PubMed Web of Science ®Google Scholar
• Buggey J, Mentz RJ, Pitt B, et al. A reappraisal of loop diuretic choice in heart failure patients. Am Heart J. 2015;169(3):323–333.
   PubMed Web of Science ®Google Scholar
• Mentz RJ, Buggey J, Fiuzat M, et al. Torsemide versus furosemide in heart failure patients: insights from Duke University Hospital. J Cardiovasc Pharmacol. 2015;65(5):438–443.
   PubMed Web of Science ®Google Scholar
• Mentz RJ, Velazquez EJ, Metra M, et al. Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial. Future Cardiol. 2015;11(5):585–595.
   PubMed Web of Science ®Google Scholar
• Mentz RJ, Hasselblad V, DeVore AD, et al. Torsemide versus furosemide in patients with acute heart failure (from the ASCEND-HF Trial). Am J Cardiol. 2016;117(3):404–411.
   PubMed Web of Science ®Google Scholar
• Rosenberg J, Gustafsson F, Galatius S, et al. Combination therapy with metolazone and loop diuretics in outpatients with refractory heart failure: an observational study and review of the literature. Cardiovasc Drugs Ther. 2005;19(4):301–306.
   PubMed Web of Science ®Google Scholar
• Channer KS, McLean KA, Lawson-Matthew P, et al. Combination diuretic treatment in severe heart failure: a randomised controlled trial. Br Heart J. 1994;71(2):146–150.
   PubMedGoogle Scholar
• Butler J, Hernandez AF, Anstrom KJ, et al. Rationale and design of the ATHENA-HF trial: aldosterone targeted neurohormonal combined with natriuresis therapy in heart failure. JACC Heart Fail. 2016;4(9):726–735.
   PubMed Web of Science ®Google Scholar
• Konstam MA, Gheorghiade M, Burnett JC, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA. 2007;297(12):1319–1331.
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Konstam MA, Burnett JC, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007;297(12):1332–1343.
   PubMed Web of Science ®Google Scholar
• Felker GM, Mentz RJ, Cole RT, et al. Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure. J Am Coll Cardiol. 2017;69(11):1399–1406.
   PubMed Web of Science ®Google Scholar
• Bart BA, Boyle A, Bank AJ, et al. Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial. J Am Coll Cardiol. 2005;46(11):2043–2046.
   PubMed Web of Science ®Google Scholar
• Costanzo MR, Guglin ME, Saltzberg MT, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007;49(6):675–683.
   PubMed Web of Science ®Google Scholar
• Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med. 2012;367(24):2296–2304.
   PubMed Web of Science ®Google Scholar
• Costanzo MR, Negoianu D, Jaski BE, et al. Aquapheresis versus intravenous diuretics and hospitalizations for heart failure. JACC Heart Fail. 2016;4(2):95–105.
   PubMed Web of Science ®Google Scholar
• Lund LH, Oldgren J, James S. Registry-based pragmatic trials in heart failure: current experience and future directions. Curr Heart Fail Rep. 2017;14(2):59–70.
   PubMedGoogle Scholar